Comparison of two ASC-derived therapeutics in an in vitro OA model: secretome versus extracellular vesicles.

These biological and molecular evidences of ASC-CM beneficial action on CH with an induced OA phenotype may lay the basis for its future clinical translation as a cell-free therapeutic in the management of OA.